Enhancing the therapeutic efficacy of bortezomib in cancer therapy using polymeric nanostructures.

CONCLUSION: There are a great number of nanoparticulate drug delivery systems for potential use in cancer therapy including non-targeted and targeted nanoparticles. Promising results to date using bortezomib nanoparticles for cancer treatment should lead to the implementation of further research with nanoparticulate-based drug delivery systems. PMID: 31692424 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research

Related Links:

Publication date: Available online 12 December 2019Source: Respiratory Medicine Case ReportsAuthor(s): Itthiphat Arunsurat, Wipa Reechaipichitkul, Apichart So-Ngern, Piti Ungareevittaya, Nipon Chaisuriya, Nattiya Teawtrakul, Pailin Ratanawatkul, Worawat ChumpangernAbstractMultiple myeloma (MM) is a hematologic malignancy of plasma cell origin. Incidence of pleural effusion in multiple myeloma patients is approximately 6%. Myelomatous pleural effusions (MPE) are rare and occur in less than 1% of all MM cases. MPE is associated with advanced diseases, decreased survival time, and poor treatment response.In our case report, w...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Publication date: Available online 13 December 2019Source: Academic RadiologyAuthor(s): Farideh Mohtasham, Jamal Rahmani, Yousef Khani, Siamak Sabour
Source: Academic Radiology - Category: Radiology Source Type: research
Authors: Knight O, Carter CR, Loranger B, Rea PM Abstract Pancreatic cancer is a leading cause of cancer related deaths in the UK. However, public knowledge and understanding of the pancreas is generally poor, therefore pancreatic cancer patients often have to contend with understanding large quantities of new information at a pivotal time in their lives.Despite utilisation of digital visualisation techniques in medical education, very rarely are they being used to help clinicians communicate information to their patients. Specifically, there is no literature describing use of an interactive digital application for...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Recent advances in molecular studies, especially genome-wide analyses, have revealed the landscape of genomic alterations present in endometrial carcinomas, and have provided valuable insight into the pathogenesis of this disease. The current challenges are in developing a molecular-morphologic classification system to enhance traditional pathologic diagnosis and in determining the optimal approach to using this new information to guide clinical management. Molecular assays may be particularly beneficial in allowing the earlier detection of endometrial cancer or precursor lesions and in guiding personalized treatment appro...
Source: International Journal of Gynecological Pathology - Category: Pathology Tags: PATHOLOGY OF THE CORPUS: REVIEW ARTICLE Source Type: research
Cowden syndrome (CS) is a multiple hamartoma syndrome associated with the development of various tumors, including endometrial cancer. However, the histology of CS-associated endometrial cancer remains to be fully described. To our knowledge, this is the first report of a patient with CS having endometrial endometrioid carcinoma with ovarian metastasis demonstrating morula-like features. A 31-yr-old, nulliparous, Japanese woman presented with abnormal genital bleeding. Endometrial biopsy revealed endometrioid carcinoma with an extensive morular formation, partially resembling atypical polypoid adenomyoma (APAM). Moreover, ...
Source: International Journal of Gynecological Pathology - Category: Pathology Tags: PATHOLOGY OF THE CORPUS: CASE REPORT Source Type: research
In this study we observed that treatment of GSH either in the pre-treatment or in the post treatment inhibited the bortezomib -induced neuronal cell death in both mouse neuronal cells (N2a) as well as dopaminergic neuron of human origin (SHSY5Y). Bortezomib treatment at the concentration of 100 and 200 µg/ml significantly increased the cell death with increased lactate dehydrogenase activity (LDH) and increased apoptotic proteins expressions in the 24 h of treatment of both cells. GSH treatment (1 mg/ml) not only inhibited the bortezomib -induced cell death but also inhibited the LDH activity, suggesting that GSH ame...
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases Source Type: research
Conclusion NCI CTCAE may be suboptimal in comparison to TNSr and TNSc in assessment of BiPN because it may miss worsening neuropathy without functional limitation. Micro-Abstract The Total Neuropathy Score is ideal for evaluation of bortezomib-induced neuropathy. We used the reduced (TNSr) and clinical (TNSc) forms as well as the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 to assess incidence of neuropathy in patients receiving cyclophosphamide, bortezomib, and dexamethasone as induction for multiple myeloma. Out of 20 evaluable patients, 55%, 40%, and 45% developed neuropathy ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions NCI-CTCAE may be suboptimal in comparison to TNSr and TNSc in assessment of BiPN as it may miss worsening neuropathy without functional limitation. Teaser Total Neuropathy Score (TNS) (reduced and clinical versions) is ideal for evaluation of bortezomib induced neuropathy. We used TNSr and TNSc along with NCI CTCAE v4.0 to assess incidence of neuropathy in patients receiving CyBorD as induction for multiple myeloma. Out of 20 evaluable patients, 55%, 40% and 45% developed neuropathy when assessed by TNSr, TNSc and NCI CTCAE respectively. We found wide variation in TNSr and TNSc even when NCI CTCAE scale reporte...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Abstract PURPOSE: Marizomib (NPI-0052) is an irreversible proteasome inhibitor, derived from a marine actinomycete, with activity and specificity that is distinct from other proteasome inhibitors. EXPERIMENTAL DESIGN: Phase 1 study (NPI-0052-102) evaluated the maximum-tolerated dose, pharmacokinetics, and pharmacodynamics of marizomib intravenously on two dosing schedules. RESULTS: Forty-two patients with advanced malignancies received Schedule A (0.1 to 0.9 mg/m2 over 1-10 minutes on Days 1, 8, 15 in 4-week cycles); 44 patients with relapsed and/or refractory multiple myeloma (RRMM) and other hematologi...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Abstract Treatment failure in cancer chemotherapy is largely due to the toxic effects of chemotherapeutic agents on normal cells/tissues. The proteasome inhibitor bortezomib has been successfully applied to treat multiple myeloma (MM), but there are some common adverse reactions in the clinic including peripheral neuropathy (PN). The TAK1 selective inhibitor 5Z-7-oxozeaenol has been widely studied in cancer therapy. Here, we investigated the potential synergy of bortezomib and 5Z-7-oxozeaenol in Burkitt’s lymphoma (BL) cell lines. Cell viability assay showed that co-treatment of bortezomib at 8 nM, repr...
Source: Tumor Biology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Drugs & Pharmacology | Lymphoma | Myeloma | Nanotechnology | Neurology | Peripheral Neuropathy | Velcade